Results 131 to 140 of about 91,755 (270)

Design, synthesis and activity evaluation of tetrahydroisoquinoline‐based programmed cell death ligand 1 inhibitors

open access: yesSmart Molecules, EarlyView.
Based on a 3D‐quantitative structure‐activity relationship pharmacophore model, structural optimization of Y6 yielded Y7f. Mechanistic studies revealed that Y7f acted as a programmed death receptor 1/programmed cell death ligand 1 (PD‐L1) interaction inhibitor by inducing PD‐L1 dimerization. Y7f restored T‐cell function.
Menglin Yu   +15 more
wiley   +1 more source

Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma

open access: yesCPT: Pharmacometrics & Systems Pharmacology
An exposure–response (E–R) safety analysis was conducted across adult and pediatric (
Shengnan Du   +7 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

Primary renal angiosarcoma: A case series and literature review

open access: yesUroPrecision, EarlyView.
Abstract Background Primary renal angiosarcoma (PRA) is an exceedingly rare and aggressive malignant vascular neoplasm of the kidney. Its imaging appearance overlaps with more common renal malignancies, making preoperative diagnosis challenging. We present four cases of histologically confirmed PRA and describe their clinical, imaging, pathologic, and ...
Ann Shi, Min Dai, Erin Zheng, James Jing
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan   +2 more
wiley   +1 more source

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li   +12 more
wiley   +1 more source

Nivolumab resistance in head and neck squamous cell carcinoma patients and future perspectives

open access: yes
Head and neck cancer (HNC) cases are increasing globally, with resistance to immunotherapies such as nivolumab posing a significant challenge. This systematic review examines the mechanisms of nivolumab resistance in HNC, with a focus on intrinsic tumor ...
Anna Mydlak   +4 more
core   +1 more source

Stage‐Specific Prognosis and Treatment Outcomes in Extramammary Paget's Disease: A Retrospective Single‐Center Study of 104 Japanese Patients

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Extramammary Paget's disease (EMPD) is a rare cutaneous malignancy for which evidence regarding stage‐specific prognosis and treatment outcomes remains limited. We retrospectively analyzed 104 patients with EMPD treated at a single Japanese institution between November 2012 and December 2025.
Manami Takahashi‐Watanabe   +7 more
wiley   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy